Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

Germain, 2010, Fabry disease, Orphanet J. Rare Dis., 5, 30, 10.1186/1750-1172-5-30 Desnick, 2016, a-Galactosidase A deficiency: Fabry disease Rozenfeld, 2017, Contribution of inflammatory pathways to Fabry disease pathogenesis, Mol. Genet. Metab., 122, 19, 10.1016/j.ymgme.2017.09.004 Amicus Therapeutics, Inc Meikle, 1999, Prevalence of lysosomal storage disorders, JAMA, 281, 249, 10.1001/jama.281.3.249 Schiffmann, 2016, Fabry disease: a disorder of childhood onset, Pediatr. Neurol., 64, 10, 10.1016/j.pediatrneurol.2016.07.001 Alegra, 2012, Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis, Genet. Mol. Biol., 35, 947, 10.1590/S1415-47572012000600009 Sirrs, 2014, Outcomes of patients treated through the Canadian Fabry disease initiative, Mol. Genet. Metab., 111, 499, 10.1016/j.ymgme.2014.01.014 Lenders, 2016, Serum-mediated inhibition of enzyme replacement therapy in Fabry disease, J. Am. Soc. Nephrol., 27, 256, 10.1681/ASN.2014121226 Hendriksz, 2018, Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders, Mol. Genet. Metab. Rep., 15, 71, 10.1016/j.ymgmr.2018.02.007 De Portu, 2008, Economic impacts of the Fabry-Anderson disease treatment, Value Health, 11, A638, 10.1016/S1098-3015(10)67081-7 Santamaria, 2019, Burden of disease in patients with Fabry disease-economic burden of health care resources consumption, Nephrol. Dial. Transplant., 34 Yam, 2005, A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder, FASEB J., 19, 12, 10.1096/fj.04-2375com Ishii, 2007, Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin, Biochem. J., 406, 285, 10.1042/BJ20070479 2020 Johnson, 2013, Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers, Clin. Pharmacol. Drug Devel., 2, 120, 10.1002/cpdd.1 Germain, 2016, Treatment of Fabry's disease with the pharmacologic chaperone migalastat, N. Engl. J. Med., 375, 545, 10.1056/NEJMoa1510198 Hughes, 2017, Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study, J. Med. Genet., 54, 288, 10.1136/jmedgenet-2016-104178 Sunder-Plassmann, 2018, Migalastat for the treatment of Fabry disease, Expert Opin. Orphan Drugs., 6, 301, 10.1080/21678707.2018.1469978 Benjamin, 2017, The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat, Genet. Med., 19, 430, 10.1038/gim.2016.122 Echevarria, 2016, X-chromosome inactivation in female patients with Fabry disease, Clin. Genet., 89, 44, 10.1111/cge.12613 Wanner, 2010, Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry, Clin. J. A. Soc. Nephrol., 5, 2220, 10.2215/CJN.04340510 Schiffmann, 2009, Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy, Nephrol. Dial. Transplant., 24, 2102, 10.1093/ndt/gfp031 Anderson, 2014, Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study, J. Inherit. Metab. Dis., 37, 969, 10.1007/s10545-014-9717-4 Weidemann, 2013, Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications, J. Intern. Med., 274, 331, 10.1111/joim.12077 Goker-Alpan, 2015, Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment naive or formerly treated with agalsidase beta or agalsidase alfa, JIMD Rep., 23, 7, 10.1007/8904_2015_422 Lenders, 2017, Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease, Nephrol. Dial. Transplant., 32, 2090 Madsen, 2018, Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study, Nephrol. Dial. Transplant., 34, 1525, 10.1093/ndt/gfy357 Mehta, 2009, Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey, J. Med. Genet., 46, 548, 10.1136/jmg.2008.065904 Patel, 2011, Cardiovascular events in patients with fabry disease natural history data from the fabry registry, J. Am. Coll. Cardiol., 57, 1093, 10.1016/j.jacc.2010.11.018 Katholi, 2011, Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications, Int. J. Hypertens., 2011, 10.4061/2011/495349 Pierdomenico, 2010, Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis, Am. J. Hypertens., 23, 876, 10.1038/ajh.2010.80 Beck, 2015, Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis, Mol. Genet. Metab. Rep., 3, 21, 10.1016/j.ymgmr.2015.02.002 Hughes, 2008, Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa, Heart, 94, 153, 10.1136/hrt.2006.104026 Germain, 2013, Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry, Genet. Med., 15, 958, 10.1038/gim.2013.53 Kampmann, 2015, Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment, Orphanet J. Rare Dis., 10, 10.1186/s13023-015-0338-2 Madsen, 2017, Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study, Scand. Cardiovasc. J., 51, 207, 10.1080/14017431.2017.1332383 Muntze, 2019, Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year, Clin. Pharmacol. Ther., 105, 1224, 10.1002/cpt.1321 Lenders, 2020, Treatment of Fabry’s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS), Clin. Pharmacol. Ther., 108, 326, 10.1002/cpt.1832 Banikazemi, 2007, Agalsidase-beta therapy for advanced Fabry disease: a randomized trial, Ann. Intern. Med., 146, 77, 10.7326/0003-4819-146-2-200701160-00148 Arends, 2018, Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study, J. Med. Genet., 55, 351, 10.1136/jmedgenet-2017-104863 Germain, 2015, Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease, J. Med. Genet., 52, 353, 10.1136/jmedgenet-2014-102797 Schiffmann, 2006, Neurological effects of enzyme replacement therapy in Fabry disease Arends, 2017, Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors, PLoS One, 12, 10.1371/journal.pone.0182379 Schiffmann, 2000, Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease, Proc. Natl. Acad. Sci. U. S. A., 97, 365, 10.1073/pnas.97.1.365 2016 Boutin, 2014, Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease, Anal. Chem., 86, 3476, 10.1021/ac404000d Mehta, 2004, Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey, Eur. J. Clin. Investig., 34, 236, 10.1111/j.1365-2362.2004.01309.x Beck, 2006, Demographics of FOS – the Fabry Outcome Survey Eng, 2007, Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry, J. Inherit. Metab. Dis., 30, 184, 10.1007/s10545-007-0521-2 Schiffmann, 2001, Enzyme replacement therapy in Fabry disease: a randomized controlled trial, JAMA, 285, 2743, 10.1001/jama.285.21.2743